Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
VTD2Bgb3GACwt6GC
